Salarius Pharmaceuticals (NASDAQ: SLRX) appeals Nasdaq delisting over $1.00 bid rule

Rhea-AI Filing Summary

Salarius Pharmaceuticals reports that Nasdaq has notified the company it is not in compliance with the exchange’s minimum bid price rule because the closing bid for its common stock was below $1.00 per share for the last 30 consecutive business days. Due to a prior reverse stock split within the last year and the company’s status under a Mandatory Panel Monitor, Salarius is not eligible for the standard 180‑day grace period normally allowed to regain compliance.

Nasdaq has determined that the company’s securities will be scheduled for delisting from The Nasdaq Capital Market and suspended at the opening of business on January 9, 2026, with a Form 25‑NSE to remove them from listing and registration, unless Salarius appeals by January 7, 2026. The company intends to request a hearing before a Nasdaq Hearings Panel and present plans to regain compliance, but it states there is no assurance of a favorable outcome or that its securities will remain listed.

Positive

• None.

Negative

• Nasdaq delisting determination: Nasdaq has determined Salarius’ securities will be suspended from The Nasdaq Capital Market on January 9, 2026, and delisted via a Form 25‑NSE unless an appeal changes this outcome.
• No grace period to regain bid‑price compliance: Because of a reverse stock split within the prior year and Mandatory Panel Monitor status, the company is not eligible for Nasdaq’s standard 180‑day compliance period after breaching the $1.00 minimum bid price.

Insights

Equity markets and listing standards analyst

Nasdaq has moved toward delisting Salarius after a bid‑price breach.

Salarius Pharmaceuticals discloses that its stock traded below $1.00 for 30 consecutive business days, triggering non‑compliance with Nasdaq’s minimum bid price rule 5550(a)(2). Because the company executed a reverse stock split within the past year and remains under a Mandatory Panel Monitor, it does not receive the usual 180‑day period to cure the deficiency under rule 5810(c)(3)(A).

Nasdaq has determined that Salarius’ securities will be suspended from The Nasdaq Capital Market at the opening on January 9, 2026, and a Form 25‑NSE will be filed to remove the securities from listing and registration, unless the company appeals by January 7, 2026. Salarius plans to request a hearing before a Nasdaq Hearings Panel and present a plan to regain compliance, while cautioning there is no assurance of a favorable decision or continued listing.

8-K Event Classification

Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

1 item

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice or transferred its listing to a different exchange.

Understanding 8-K Material Events →

0001615219FALSE00016152192025-12-192025-12-19

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 31, 2025

SALARIUS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

Delaware

001-36812

46-5087339

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification Number)

2450 Holcombe Blvd. Suite X Houston, TX

77021

(Address of principal executive offices)

(Zip Code)

(713) 913-5608
(Registrant’s telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:

Title of each class						Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.0001						SLRX			The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On December 31, 2025, Salarius Pharmaceuticals, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with Nasdaq listing rule 5550(a)(2) because the closing bid price of the Company’s common stock for the last 30 consecutive business days was lower than the minimum bid price requirement of $1.00 per share (the “Minimum Bid Price Requirement”). Normally, a company would be afforded a 180-calendar day period to demonstrate compliance with the Minimum Bid Price Requirement. However, pursuant to Nasdaq listing rule 5810(c)(3)(A)(iv) and the Company remaining subject to a Mandatory Panel Monitor, the Company is not eligible for any compliance period specified in Nasdaq listing rule 5810(c)(3)(A) because the Company has effected a reverse stock split during the prior one-year period.

Accordingly, unless the Company requests an appeal of the delisting determination by January 7, 2026, Nasdaq has determined that the Company’s securities will be scheduled for delisting from The Nasdaq Capital Market and will be suspended at the opening of business on January 9, 2026. In addition, a Form 25-NSE will be filed with the Securities and Exchange Commission (the “SEC”), which will remove the Company’s securities from listing and registration on The Nasdaq Stock Market.

The Company intends to appeal the delisting determination on or before January 7, 2026 by requesting an appeal with a Nasdaq Hearings Panel (the “Hearings Panel”). A request for an appeal will stay the suspension of the Company’s securities and the filing of the Form 25-NSE pending the Hearings Panel’s decision. The Company intends to present its plans to regain compliance with the Minimum Bid Price Requirement. However, there are no assurances a favorable decision from the Hearing Panel will be obtained or that the Company’s securities will remain listed on The Nasdaq Capital Market.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SALARIUS PHARMACEUTICALS, INC.

Date: January 2, 2026

By:

/s/ Mark J. Rosenblum

Mark J. Rosenblum Executive Vice President & Chief Financial Officer

FAQ

Why did Salarius Pharmaceuticals (SLRX) receive a Nasdaq non-compliance notice?

Salarius Pharmaceuticals received a notice because the closing bid price of its common stock was below $1.00 per share for the last 30 consecutive business days, violating Nasdaq listing rule 5550(a)(2).

What action has Nasdaq taken regarding Salarius Pharmaceuticals listing?

Nasdaq has determined that Salarius securities will be scheduled for delisting from The Nasdaq Capital Market and suspended at the opening of business on January 9, 2026, with a Form 25-NSE to remove the securities from listing and registration, unless an appeal is made.

Does Salarius Pharmaceuticals (SLRX) get a 180-day period to fix its bid price?

No. Under Nasdaq listing rule 5810(c)(3)(A)(iv), Salarius is not eligible for the standard 180-calendar day compliance period because it effected a reverse stock split during the prior one-year period and remains subject to a Mandatory Panel Monitor.

How is Salarius Pharmaceuticals responding to the Nasdaq delisting determination?

The company intends to appeal the delisting determination by requesting a hearing with a Nasdaq Hearings Panel on or before January 7, 2026, and plans to present steps to regain compliance with the minimum bid price requirement.

Is there any guarantee Salarius Pharmaceuticals will remain listed on Nasdaq?

No. Salarius states there are no assurances that the Nasdaq Hearings Panel will issue a favorable decision or that the companys securities will remain listed on The Nasdaq Capital Market.

What is the minimum bid price requirement affecting Salarius Pharmaceuticals stock?

Under Nasdaq listing rule 5550(a)(2), Salarius common stock must maintain a minimum bid price of $1.00 per share; trading below this level for 30 consecutive business days led to the non-compliance notice.